김혜민 (경북대학교)

윤영란 (경북대학교)

박진주 (경북대학교)

김혜민 (경북대학교)

박지서 (경북대학교)

권미리 (경북대학교)

이혜원 (경북대학교)

성숙진 (경북대학교)

윤영란 (경북대학교)

Dapagliflozin is a medication that reduces blood glucose levels in patients with type 2 diabetes. Additionally, it is well-known that dapagliflozin induces metabolic changes that promote weight loss by utilizing fats and ketone bodies instead of glucose for energy production. Weight loss resulting from dapagliflozin has been observed in healthy individuals with normal and high body mass index (BMI). However, there is a lack of studies on the metabolic changes in both groups. Therefore, we aim to investigate metabolic changes after administering dapagliflozin to both healthy normal and obese groups.

Thirteen participants in the normal group (BMI, 22.9 ± 1.9 kg/m²) and nine participants in the obese group (BMI, 31.4 [34.1–41.8] kg/m²) were orally administered dapagliflozin at a dosage of 10 mg per day for five days. Urine samples were collected before and after dapagliflozin administration and analyzed using ultra high performance liquid chromatography and quadrupole time-of-flight/mass spectrometry in positive and negative ion modes. Putative endogenous metabolites were considered with variable importance in the projection values ≥ 1.0 and p-value < 0.05.

After dapagliflozin administration, 26 and 36 putative metabolites such as amino acids, fatty acids, and oligopeptides were annotated in the normal and obese groups, respectively. In both groups, levels of glucogenic amino acids and fatty acids decreased, while ketogenic amino acids increased. Additionally, 14 commonly annotated putative metabolites, such as amino acids and fatty acids, were found in both groups. However, there was no difference in their changes between the two groups. All putative metabolites that changed after the administration of dapagliflozin were associated with energy metabolism, such as the TCA cycle, gluconeogenesis, and ketone synthesis. Further studies are needed to compare the energy metabolism induced in a healthy normal group and an obese group after the administration of dapagliflozin.